CISN - Research Hallmarks: Circa Today -Tumor Epigenetics
| You Are Here: Home > Cancer Research > What We Know About Cancer > Advances In Cancer Research > Research Hallmarks: Circa Today -Tumor Epigenetics | |||
Tumor Epigenetics:
|
![]() |
Epigenetic damage (seen here in more widespread darker areas) accumulates as we age. The DNA on the left is from an eight-year- old, while the corresponding stretch of DNA on the right is from a 60-year-old. |
| Section Index | |
| ● | What We Know About Cancer |
| How Cancer is Studied | |
| Drug Development | |
| New Treatments | |
| Research Advocacy | |
Two types of epigenetic changes are described below:1) MethylationIn this alteration, some parts of the DNA are modified by the addition of a methyl (-CH3) group to the base. A chemical reaction in which a small molecule called a methyl group is added to other molecules. Methylation of proteins or nucleic acids may affect how they act in the body. Methylation of DNA is associated with the inactivation of that particular region of DNA. Abnormal DNA methylation patterns have been seen in cancer cells. Methylation alters the expression of the affected genes.
2) Acetylation
Much remains unknown about the role of epigenetic factors and cancer. Since some epigenetic changes are reversible through modifications to genes or proteins that occur in the tumor and its microenvironment, companies are now looking to develop new treatments to target these areas. Epigenetic Carcinogens:A variety of compounds are considered epigenetic carcinogens (i.e., they result in an increased incidence of tumors), but they do not show DNA mutations. Examples include:
Epigenetic Treatments:These drugs are often referred to as demethylating agents. This is still a new field so expect more drugs to become available on an ongoing bases. Myelodysplastic syndrome (MDS):
Cutaneous T-cell lymphoma
CISN Summary:
|
||||||||||||
| |


